Shionogi invests 2.13 billion dollars in ViiV Healthcare as Pfizer exits
Shionogi & Co will pay 2.13 billion dollars to increase its stake in HIV drugmaker ViiV Healthcare to 21.7 percent. Pfizer is exiting the joint venture today.
Insights:
Shionogi & Co Ltd , a pharmaceutical firm based in Japan 
JP, announced on Tuesday, January 20, 2026, that it will pay $2.13 billion for new shares in the HIV drugmaker ViiV Healthcare. This capital investment marks a significant strategic repositioning within the global HIV therapeutics market. Upon completion of the transaction, the ownership stake held by Shionogi & Co Ltdin the joint venture will increase to 21.7 percent.
JP, announced on Tuesday, January 20, 2026, that it will pay $2.13 billion for new shares in the HIV drugmaker ViiV Healthcare. This capital investment marks a significant strategic repositioning within the global HIV therapeutics market. Upon completion of the transaction, the ownership stake held by Shionogi & Co Ltdin the joint venture will increase to 21.7 percent.
